Bill
Bill > S808
MA S808
MA S808Relative to cancer patient access to biomarker testing to provide appropriate therapy
summary
Introduced
03/29/2021
03/29/2021
In Committee
03/29/2021
03/29/2021
Crossed Over
Passed
Dead
12/31/2022
12/31/2022
Introduced Session
192nd General Court
Bill Summary
For legislation relative to cancer patient access to biomarker testing to provide appropriate therapy. Health Care Financing.
AI Summary
This bill prohibits health insurance plans in Massachusetts from requiring prior authorization for biomarker testing for individuals with advanced or metastatic stage 3 or 4 cancer, as well as for testing related to cancer progression or recurrence. Biomarker testing refers to diagnostic tests of a cancer patient's tissue, blood, or other bodily fluids to identify DNA or RNA alterations that can help guide the patient's treatment. The bill applies to various types of health insurance plans, including those offered by the state's Group Insurance Commission, MassHealth (the state's Medicaid program), and private insurers.
Committee Categories
Health and Social Services
Sponsors (2)
Last Action
Accompanied a study order, see S2917 (on 06/09/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://malegislature.gov/Bills/192/S808 |
| Bill | https://malegislature.gov/Bills/192/S808.pdf |
Loading...